Back to Search Start Over

Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: A promising option for detection of cervical malignancies in remote areas.

Authors :
Torres KL
Mariño JM
Pires Rocha DA
de Mello MB
de Melo Farah HH
Reis RDS
Alves VDCR
Gomes E
Martins TR
Soares AC
de Oliveira CM
Levi JE
Source :
PloS one [PLoS One] 2018 Jul 23; Vol. 13 (7), pp. e0201262. Date of Electronic Publication: 2018 Jul 23 (Print Publication: 2018).
Publication Year :
2018

Abstract

Objective: To evaluate both the performance and acceptability of a method coupling self-sampling with detection of cervical malignancy via elevated HPV 16 and 18 E6 oncoproteins (OncoE6™ Cervical Test) in remote areas in Brazil.<br />Methods: Women living in rural villages in proximity to Coari city, Amazonas, Brazil were invited to participate in a cervical cancer screening study. 412 subjects were enrolled; there were no refusals. In addition to E6 protein detection, DNA was extracted from the brushes and evaluated for HPV genotypes by PCR (PGMY09/11), followed by typing by the Papillocheck™ if positive. Subjects who were found to be positive for OncoE6 or HPV-DNA were referred for colposcopy.<br />Results: For 110 subjects (27%) this was the first cervical cancer exam. Overall the HPV-DNA prevalence was 19.1% (n = 79); 1.4% (n = 6) were positive by the OncoE6 Test. Fifty-six women attended the invitation for colposcopy where nine had an abnormal cervix and were subsequently biopsied. Histopathological analysis revealed 2 CIN3, 2 carcinomas and 5 CIN1. OncoE6 called two out of the three HPV 16 or 18 associated CIN3+ lesions.<br />Conclusions: The findings suggest that self-administered sample collection in combination with OncoE6 Test is feasible in this population. This could enable expanded screening coverage while ensuring a high specificity which is imperative given the remote geographic location, since women bearing abnormal test results would necessitate travel and logistical burden to access colposcopy and treatment.<br />Competing Interests: JE Levi has received travel support from Arbor Vita Corporation, research support in the form of equipment and reagents from BD and speakers fee from Roche Diagnostics in the last 5 years. Other authors do not have any potential conflict of interest to disclose.

Details

Language :
English
ISSN :
1932-6203
Volume :
13
Issue :
7
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
30036381
Full Text :
https://doi.org/10.1371/journal.pone.0201262